Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2023-02-06 Earnings Release
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
2022年年度业绩预告公告
Earnings Release Classification · 95% confidence The document is a 2022 annual performance forecast announcement by Jiangsu Deyuan Pharmaceutical Co., Ltd. It provides preliminary financial data for the full year 2022, including estimated net profit and reasons for performance changes. It explicitly states that the data are preliminary, unaudited, and subject to the final audited annual report. The document is short (976 characters) and serves as a forecast or earnings preview rather than a full annual report or audited financial statement. It is not a full earnings release with finalized results but a performance outlook. Such documents are typically classified as Earnings Release (ER) because they announce key financial results or forecasts for a period, highlighting expected profitability and changes compared to the prior year. It is not an Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements and is preliminary. It is not a Report Publication Announcement (RPA) because it contains substantive financial forecast data, not just a notice of report availability. FY 2022
2023-02-06 Chinese
关于卡格列净片（0.1g）获国家药监局签发药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the issuance of a drug registration certificate by the National Medical Products Administration for a specific pharmaceutical product (Kagrelizine tablets 0.1g). It includes details about the drug, its approval, and potential impact on the company. The document is short (1258 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed corporate filing. It does not contain financial data, management changes, or meeting materials. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-01-11 Chinese
高级管理人员辞职公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a senior management personnel (Vice General Manager) of the company, including details about the resignation date, shareholding, and impact on the company. It does not contain financial data, audit information, or report content. It specifically relates to changes in senior management. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on management change, confirming this classification.
2022-12-14 Chinese
关于坎地氢噻片首家通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the approval of their drug (Candesartan Hydrochlorothiazide tablets) passing the generic drug consistency evaluation. It includes details about the drug, regulatory approval, and potential impact on the company. The document is relatively short (1421 characters) and serves as a formal announcement of a regulatory approval event rather than a financial report or detailed corporate filing. There is no financial data, no mention of annual or quarterly results, no management discussion, no audit information, or other report types. It is a regulatory announcement about a product approval and its implications. Therefore, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-12-05 Chinese
国浩律师（南京）事务所关于江苏德源药业股份有限公司 2022 年第四次临时股东大会之法律意见书
Regulatory Filings
2022-11-10 Chinese
2022年第四次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2022 fourth extraordinary general meeting of shareholders of Jiangsu Deyuan Pharmaceutical Co., Ltd. It includes information about the meeting's convening, attendance, voting results on various proposals, legal opinions, and changes in board members. The content focuses on the outcomes of shareholder votes and meeting procedures rather than presenting financial data or management analysis. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 2612 characters, which is consistent with a detailed voting results announcement rather than a full report or presentation. Therefore, the correct classification is DVA with high confidence.
2022-11-10 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.